SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Amexdrug Corporation AXRX OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Amexdrug Corporation (AXRX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Financials: revenue is $3M, -15.5%/yr average growth. Net income is $40,275, growing at +44.1%/yr. Net profit margin is 1.4% (thin). Gross margin is 39.6% (+19 pp trend).

Balance sheet: total debt is $431,318 against $2M equity (Debt-to-Equity (D/E) ratio 0.24, conservative). Current ratio is 8.78 (strong liquidity). Debt-to-assets is 17.1%. Total assets: $3M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 100/100 (Pass), Health 67/100 (Partial), Moat 36/100 (Fail), Future ?/100 (Fail), Income 30/100 (Fail).

AXRX SharesGrow Score Overview

65/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 36/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 30/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AXRX

AXRX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

AXRX: -15.5%/yr revenue is, +44.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

AXRX: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet AXRX: Debt-to-Equity (D/E) ratio 0.24 (conservative), Current ratio is 8.78 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

AXRX: Gross margin is 39.6% (+19 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 36/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

AXRX: Net profit margin is 1.4%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0001-0.002

Volume100

Avg Volume (30D)52

Market Cap$33.88K

Beta (1Y)-0.54

Share Statistics

EPS (TTM)0.00

Shares Outstanding$169.41M

IPO Date2001-03-29

Employees9

CEOJack Amin

Financial Highlights & Ratios

Revenue (TTM)$2.9M

Gross Profit$1.15M

EBITDA$136.79K

Net Income$40.28K

Operating Income$136.79K

Total Cash$1.7M

Total Debt$431.32K

Net Debt$383.82K

Total Assets$2.52M

Price / Earnings (P/E)1

Price / Sales (P/S)0.01

Analyst Forecast

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS0311392072

Price Chart

AXRX

Amexdrug Corporation ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

0.00 52WK RANGE 0.00

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message